Rockwell Medical Reports Fourth Quarter 2007 Results;Year-end Sales Increase 50%
Rockwell Medical Reports Fourth Quarter 2007 Results; Year-end Sales Increase 50%WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative manufacturer and developer of renal drug therapies and essential dialysate products, reported record fourth quarter 2007 sales of $11.95 million, up 29.5% as compared to $9.2 million for the same period of 2006. Loss per share for the fourth quarter was ($.09) vs. ($.10) for the same period of 2006.
Year end 2007 results were highlighted by record sales of $43 million, increasing over 50% as compared to $28.6 million in 2006. Loss for the year ended 2007 was ($.32) vs. ($.41) in 2006.
- Record quarterly revenue $11,948,905 up 29.5% over fourth quarter 2006.
- Sequential revenue growth of 7.9% over third quarter 2007.
- Loss per share ($.09) a $.01 improvement compared to ($.10) in 2006.
- Revenue increased to $43 million, up 50% in 2007 compared to 2006.
- Domestic sales increased greater than 70% in 2007.
- Research and development costs were $3.26 million in 2007.
- Loss per share ($.32) a $.09 improvement compared to ($.41) in 2006.
- RMTI stock upgraded to the Nasdaq Global Market Exchange in January 2007.
- Commenced Phase II-b clinical study
- Raised gross proceeds of $12.9 million in November 2007 to fund on-going FDA clinical trial.
- Completed protocol to begin NIH-funded study.
- Completed pre-clinical safety pharmacology and toxicology studies for SFP.
- Received final safety pharm/toxicology reports demonstrating strong safety profile for SFP.
- Patent grants received for Japan and Mexico.
Mr. Robert L. Chioini, Chairman and CEO stated, “Our
fourth quarter marked a significant milestone for our SFP drug development
program. We commenced our Phase II-b human clinical study and successfully
completed a capital raise of nearly $13 million, which we expect will fund our
current FDA clinical development program.”
Mr. Chioini also stated, “Our concentrate sales increased significantly in 2007 but rising inflation in our primary cost drivers temporarily pressured our gross margins in the fourth quarter. Going forward, we anticipate margin improvement in our concentrate business as we pass on inflationary costs to our customer base, and we expect to continue to solidify our market position which is currently over 26% of the dialysis provider market.”
Rockwell will be hosting a conference call to review its 2007 and fourth quarter results on Thursday, March 6, 2008 at 11:00 am EST. Investors are encouraged to call in several minutes in advance at (888) 661-5174 to hear the call or they may listen on the web at the following link: http://investor.shareholder.com/media/eventdetail.cfm?mediaid=30039&c=RMTI&mediakey=2ABCD2DFF357359EB5B2BDFF66F876B3&e=0
See www.rockwellmed.com for more details and playback options.
Rockwell Medical Technologies, Inc. is a leading, innovative manufacturer and developer of renal drug therapies and critical products focused on improving the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients whose kidneys have failed to work and who suffer from chronic kidney failure, a condition also known as end-stage-renal-disease (ESRD). There are an estimated 360,000 ESRD patients in the United States growing approximately 3-5% on average each year. There are approximately 2 million ESRD patients world-wide. Rockwell's products are used to maintain life, removing toxins and replacing nutrients in the dialysis patient's bloodstream. Rockwell has licensed and is currently developing proprietary renal drug therapies for both iron-delivery and carnitine/vitamin-delivery, utilizing its dialysate as the delivery mechanism. These exclusive renal drug therapies support disease management initiatives to improve the quality of care for dialysis patients and are designed to deliver safe and effective therapy to patients while decreasing nursing time and supply cost. The Company offers the proprietary Dri-Sate® Dry Acid Concentrate Mixing System, RenalPure® Liquid Acid Concentrate, SteriLyte® Liquid Bicarbonate Concentrate, RenalPure® Powder Bicarbonate Concentrate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.
Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. When we use words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "projected," "intend" or similar expressions, or make statements regarding our intent, belief, or current expectations, we are making forward-looking statements. While we believe these forward-looking statements are reasonable, you should not place undue reliance on any such forward-looking statements which are based on information available to us on the date of this release. Because these forward looking statements are based upon estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond our control or are subject to change, actual results could be materially different. Factors which could cause such a difference include, without limitation, the risk factors and other risks and uncertainties set forth in the Company's SEC filings, including its Form 10-KSB for the year ended December 31, 2006 and its Forms 10-Q filed during 2007. The forward- looking statements should be considered in light of these risks and uncertainties. We do not undertake, and expressly disclaim any obligation, to update or alter our statements whether as a result of new information, future events or otherwise, except as required by law.
Consolidated Income Statements
For the three and twelve months ended
December 31, 2007 and December 31, 2006
|3 Months ended Dec 31, 2007||3 Months ended Dec 31, 2006||12 Months ended Dec 31, 2007||12 Months ended Dec 31, 2006|
|Sales||$ 11,948,905||$ 9,228,502||$ 43,045,304||$ 28,638,859|
|Cost of Sales||11,073,295||8,268,797||40,015,466||25,837,294|
|Selling, General, Admin||1,084,987||748,875||3,374,458||2,801,565|
|Research & Product Devel.||944,281||1,396,333||3,263,733||4,777,976|
|Interest Expense (Income), net||9,185||(30,468)||110,542||(62,851)|
|Basic Earnings (Loss) per share||$ (0.09)||$ (0.10)||$ (0.32)||$ 0.41|
|Diluted Earnings (Loss) per share||$ (0.09)||$ (0.10)||$ (0.32)||$ 0.41|
Consolidated Balance Sheets
As of December 31, 2007 and December 31, 2006
|Dec. 31, 2007||Dec. 31, 2006|
|Cash and Cash Equivalents||$ 11,097,092||$ 2,662,873|
net of a reserve of $66,085 in 2007 and $72,500 in 2006
|Other Current Assets||302,573||261,473|
|Total Current Assets||18,645,945||9,058,846|
|Property and Equipment, net||2,840,331||2,587,771|
|Other Non-current Assets||125,667||127,625|
Liabilities and Shareholders' Equity
|Notes Payable & Capitalized Lease Obligations||194,239||369,551|
|Total Current Liabilities||4,637,271||4,452,675|
Long Term Notes Payable & Capitalized Lease Obligations
|Common Shares, no par value,
13,815,186 and 11,5500,349 shares issued and outstanding
|Common Share Purchase Warrants,
1,204,169 and -0- shares issued and outstanding
|Total Shareholders' Equity||17,961,026||8,374,113|
|Total Liabilities and Shareholders' Equity||$22,803,134||$13,152,833|
(return to News Index)